Germany · Delayed Price · Currency is EUR Atai Life Sciences Statistics
Total Valuation
ETR:9VC has a market cap or net worth of EUR 702.94 million. The enterprise value is 631.63 million.
| Market Cap | 702.94M |
| Enterprise Value | 631.63M |
Important Dates
The last earnings date was Friday, August 15, 2025.
| Earnings Date | Aug 15, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 212.14M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +7.97% |
| Shares Change (QoQ) | +11.51% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 122.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 357.53 |
| PB Ratio | 5.74 |
| P/TBV Ratio | 5.88 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -6.21 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.02, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.02 |
| Quick Ratio | 3.76 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -30.60 |
Financial Efficiency
Return on equity (ROE) is -76.50% and return on invested capital (ROIC) is -34.47%.
| Return on Equity (ROE) | -76.50% |
| Return on Assets (ROA) | -29.51% |
| Return on Invested Capital (ROIC) | -34.47% |
| Return on Capital Employed (ROCE) | -58.41% |
| Revenue Per Employee | 36,410 |
| Profits Per Employee | -1.88M |
| Employee Count | 54 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -550,921 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +197.27% in the last 52 weeks. The beta is 1.55, so ETR:9VC's price volatility has been higher than the market average.
| Beta (5Y) | 1.55 |
| 52-Week Price Change | +197.27% |
| 50-Day Moving Average | 2.61 |
| 200-Day Moving Average | 1.76 |
| Relative Strength Index (RSI) | 54.07 |
| Average Volume (20 Days) | 4,396 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 2.89 |
Income Statement
In the last 12 months, ETR:9VC had revenue of EUR 1.97 million and -101.67 million in losses. Loss per share was -0.59.
| Revenue | 1.97M |
| Gross Profit | 1.97M |
| Operating Income | -81.40M |
| Pretax Income | -102.32M |
| Net Income | -101.67M |
| EBITDA | -80.77M |
| EBIT | -81.40M |
| Loss Per Share | -0.59 |
Balance Sheet
The company has 81.70 million in cash and 10.43 million in debt, giving a net cash position of 71.27 million.
| Cash & Cash Equivalents | 81.70M |
| Total Debt | 10.43M |
| Net Cash | 71.27M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 122.55M |
| Book Value Per Share | 0.62 |
| Working Capital | 65.68M |
Cash Flow
| Operating Cash Flow | n/a |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -4,140.32% |
| Pretax Margin | -5,203.98% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ETR:9VC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -7.97% |
| Shareholder Yield | n/a |
| Earnings Yield | -14.46% |
| FCF Yield | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |